Mitochondrial cardiomyopathy: Pathophysiology, diagnosis, and management

Texas Heart Institute Journal

Volumn 40, Issue 4, 2013, Pages 385-394

  Meyers, Deborah E ^a   Basha, Haseeb Ilias ^b   Koenig, Mary Kay ^c  

^a TEXAS HEART INSTITUTE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cardiomyopathies; DNA, mitochondrial analysis genetics; Electron transport physiology; Energy metabolism physiology; Genetic predisposition to disease; Genetics pathology therapy; Heart diseases genetics; Mitochondria physiology; Mitochondrial diseases complications diagnosis genetics physiopathology drug therapy; Risk factors; Ventricular dysfunction, left genetics

Indexed keywords

ALPHA TOCOPHEROL; AMINOGLYCOSIDE; ARGININE; ASCORBIC ACID; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE; CHLORAMPHENICOL; CREATINE; DICHLOROACETIC ACID; DIHYDROLIPOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FOLIC ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDEBENONE; INFUSION FLUID; METFORMIN; MITOCHONDRIAL DNA; PROPOFOL; RIBOFLAVIN; STREPTOMYCIN; TETRACYCLINE DERIVATIVE; THIAMINE; UBIDECARENONE; VALPROIC ACID;

CARDIOMYOPATHY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DISEASE MANAGEMENT; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CONTRAINDICATION; EVOLUTIONARY ADAPTATION; GENE MUTATION; HEADACHE; HEART DISEASE; HUMAN; HYPERKALEMIA; HYPOTENSION; LOADING DRUG DOSE; MELAS SYNDROME; MITOCHONDRIAL CARDIOMYOPATHY; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRION; MUSCLE BIOPSY; NAUSEA; PATHOPHYSIOLOGY; POLYNEUROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; VOMITING;

CARDIOMYOPATHIES/GENETICS/PATHOLOGY/THERAPY; DNA, MITOCHONDRIAL/ANALYSIS/GENETICS; ELECTRON TRANSPORT/PHYSIOLOGY; ENERGY METABOLISM/PHYSIOLOGY; GENETIC PREDISPOSITION TO DISEASE; HEART DISEASES/GENETICS; MITOCHONDRIA/PHYSIOLOGY; MITOCHONDRIAL DISEASES/COMPLICATIONS/DIAGNOSIS/GENETICS/PHYSIOPATHOLOGY/DRUG THERAPY; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT/GENETICS;

ANIMALS; CARDIOMYOPATHIES; DNA, MITOCHONDRIAL; ENERGY METABOLISM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIA, HEART; MITOCHONDRIAL DISEASES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84884971301     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol 2010; 5:297-348.
2. Venditti P, Di Stefano L, Di Meo S. Mitochondrial metabolism of reactive oxygen species. Mitochondrion 2013; 13(2):71-82.
3. Wallace DC. The epigenome and the mitochondrion: bioenergetics and the environment [corrected] [published erratum appears in Genes Dev 2010; 24(17):1961]. Genes Dev 2010; 24(15):1571-3.
4. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008; 83(2):254-60.
5. Chinnery PF, Elliott HR, Hudson G, Samuels DC, Relton CL. Epigenetics, epidemiology and mitochondrial DNA diseases. Int J Epidemiol 2012; 41(1):177-87.
6. Lane N. Evolution. The costs of breathing. Science 2011; 334 (6053):184-5.
7. Wallace DC. Why do we still have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine. Annu Rev Biochem 2007; 76:781-821.
8. Wai T, Teoli D, Shoubridge EA. The mitochondrial DNA genetic bottleneck results from replication of a subpopulation of genomes. Nat Genet 2008; 40(12):1484-8.
9. Limongelli G, Masarone D, D'Alessandro R, Elliott PM. Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course. Future Cardiol 2012; 8(1):71-88.
10. Freyer C, Cree LM, Mourier A, Stewart JB, Koolmeister C, Milenkovic D, et al. Variation in germline mtDNA heteroplasmy is determined prenatally but modified during subsequent transmission. Nat Genet 2012; 44(11):1282-5.
11. Sacconi S, Salviati L, Nishigaki Y, Walker WF, Hernandez-Rosa E, Trevisson E, et al. A functionally dominant mitochondrial DNA mutation. Hum Mol Genet 2008; 17(12):1814-20.
12. Hirano M, Davidson M, DiMauro S. Mitochondria and the heart. Curr Opin Cardiol 2001; 16(3):201-10.
13. Nachman MW, Brown WM, Stoneking M, Aquadro CF. Nonneutral mitochondrial DNA variation in humans and chimpanzees. Genetics 1996; 142(3):953-63.
14. Schriner SE, Ogburn CE, Smith AC, Newcomb TG, Ladiges WC, Dolle ME, et al. Levels of DNA damage are unaltered in mice overexpressing human catalase in nuclei. Free Radic Biol Med 2000; 29(7):664-73.
15. Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 2003; 24(3):280-8.
16. Koenig MK. Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol 2008; 38(5):305-13.
17. DiMauro S. Mitochondrial myopathies. Curr Opin Rheumatol 2006; 18(6):636-41.
18. DiMauro S, Hirano M. Mitochondrial encephalomyopathies: an update. Neuromuscul Disord 2005; 15(4):276-86.
19. Debray FG, Lambert M, Chevalier I, Robitaille Y, Decarie JC, Shoubridge EA, et al. Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. Pediatrics 2007; 119(4):722-33.
20. Petty RK, Harding AE, Morgan-Hughes JA. The clinical features of mitochondrial myopathy. Brain 1986; 109(Pt 5):915-38.
21. Munnich A, Rotig A, Chretien D, Cormier V, Bourgeron T, Bonnefont JP, et al. Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis 1996; 19(4):521-7.
22. Jackson MJ, Schaefer JA, Johnson MA, Morris AA, Turnbull DM, Bindoff LA. Presentation and clinical investigation of mitochondrial respiratory chain disease. A study of 51 patients. Brain 1995; 118(Pt 2):339-57.
23. DiMauro S, Bonilla E, De Vivo DC. Does the patient have a mitochondrial encephalomyopathy? J Child Neurol 1999; 14 Suppl 1:S23-35.
24. Rotig A. Renal disease and mitochondrial genetics. J Nephrol 2003; 16(2):286-92.
25. Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, Thorburn DR. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002; 59(9):1406-11.
26. Hsu CH, Kwon H, Perng CL, Bai RK, Dai P, Wong LJ. Hearing loss in mitochondrial disorders. Ann N Y Acad Sci 2005; 1042:36-47.
27. Finsterer J. Central nervous system manifestations of mitochondrial disorders. Acta Neurol Scand 2006; 114(4):217-38.
28. Gillis LA, Sokol RJ. Gastrointestinal manifestations of mitochondrial disease. Gastroenterol Clin North Am 2003; 32(3): 789-817
29. Engel WK, Cunningham GG. Rapid examination of muscle tissue. An improved trichrome method for fresh-frozen biopsy sections. Neurology 1963; 13:919-23.
30. Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, Munnich A. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228(1):35-51.
31. Rustin P, Chretien D, Bourgeron T, Wucher A, Saudubray JM, Rotig A, Munnich A. Assessment of the mitochondrial respiratory chain. Lancet 1991; 338(8758):60.
32. Taylor GP. Neonatal mitochondrial cardiomyopathy. Pediatr Dev Pathol 2004; 7(6):620-4.
33. Finsterer J. Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction. Pediatr Cardiol 2009; 30(5):659-81.
34. Anan R, Nakagawa M, Miyata M, Higuchi I, Nakao S, Suehara M, et al. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 1995; 91(4):955-61.
35. Wahbi K, Larue S, Jardel C, Meune C, Stojkovic T, Ziegler F, et al. Cardiac involvement is frequent in patients with the m.8344A>G mutation of mitochondrial DNA. Neurology 2010; 74(8):674-7.
36. Stollberger C, Finsterer J, Blazek G. Left ventricular hypertrabeculation/ noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. Am J Cardiol 2002; 90(8):899-902.
37. Jenni R, Oechslin EN, van der Loo B. Isolated ventricular non-compaction of the myocardium in adults. Heart 2007; 93 (1):11-5.
38. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart 2001; 86(6):666-71.
39. Thavendiranathan P, Dahiya A, Phelan D, Desai MY, Tang WH. Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. Heart 2013; 99(10):681-9.
40. Kohli SK, Pantazis AA, Shah JS, Adeyemi B, Jackson G, McKenna WJ, et al. Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? Eur Heart J 2008; 29(1):89-95.
41. Sebastiani M, Giordano C, Nediani C, Travaglini C, Borchi E, Zani M, et al. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll Cardiol 2007; 50(14):1362-9.
42. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005; 115(3): 547-55.
43. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 1994; 267(2 Pt 2):H742-50.
44. Bishop SP, Altschuld RA. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 1970; 218(1):153-9.
45. Christe ME, Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol 1994; 26(10):1371-5.
46. Sambandam N, Lopaschuk GD, Brownsey RW, Allard MF. Energy metabolism in the hypertrophied heart. Heart Fail Rev 2002; 7(2):161-73.
47. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 1988; 11(5):416-26.
48. Arbustini E, Diegoli M, Fasani R, Grasso M, Morbini P, Banchieri N, et al. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am J Pathol 1998; 153(5):1501-10.
49. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002; 109(1):121-30.
50. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006(1):CD004426.
51. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010; 42(5):739-48.
52. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20(12):1502-9.
53. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006; 66(3):324-30.
54. Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005; 64(4):710-2.
55. Martin DS, Grocott MP. Oxygen therapy in critical illness: precise control of arterial oxygenation and permissive hypoxemia. Crit Care Med 2013; 41(2):423-32.
56. Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci 2010; 1201:104-10.
57. Flynn NE, Meininger CJ, Haynes TE, Wu G. The metabolic basis of arginine nutrition and pharmacotherapy. Biomed Pharmacother 2002; 56(9):427-38.
58. Haberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 2012; 7:32.
59. Golden AS, Law YM, Shurtleff H, Warner M, Saneto RP. Mitochondrial electron transport chain deficiency, cardiomyopathy, and long-term cardiac transplant outcome. Pediatr Transplant 2012; 16(3):265-8.